BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 15665842)

  • 1. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
    Oran B; Malek K; Sanchorawala V; Wright DG; Quillen K; Finn KT; La Valley M; Skinner M; Seldin DC
    Bone Marrow Transplant; 2005 Mar; 35(6):567-75. PubMed ID: 15665842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.
    Lee S; Kim S; Kim H; Baek EJ; Jin H; Kim J; Kim HO
    Vox Sang; 2008 Feb; 94(2):146-52. PubMed ID: 18028260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34(+) cell dose.
    Keever-Taylor CA; Klein JP; Eastwood D; Bredeson C; Margolis DA; Burns WH; Vesole DH
    Bone Marrow Transplant; 2001 Apr; 27(8):791-800. PubMed ID: 11477435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD34+ cell responsiveness to stromal cell-derived factor-1alpha underlies rate of engraftment after peripheral blood stem cell transplantation.
    Marquez-Curtis LA; Turner AR; Larratt LM; Letcher B; Lee SF; Janowska-Wieczorek A
    Transfusion; 2009 Jan; 49(1):161-9. PubMed ID: 18954402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
    Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
    Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term engraftment failure after marrow ablation and autologous hematopoietic reconstitution: differences between peripheral blood stem cell and bone marrow recipients.
    Bentley SA; Brecher ME; Powell E; Serody JS; Wiley JM; Shea TC
    Bone Marrow Transplant; 1997 Mar; 19(6):557-63. PubMed ID: 9085735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose.
    Stewart DA; Guo D; Luider J; Auer I; Klassen J; Morris D; Chaudhry A; Brown C; Russell JA; Gluck S
    Bone Marrow Transplant; 2000 Feb; 25(4):435-40. PubMed ID: 10723588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
    Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
    Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD34 subsets on engraftment kinetics in allogeneic peripheral blood stem cell transplantation.
    Kamel AM; El-Sharkawy N; Mahmoud HK; Khalaf MR; El Haddad A; Fahmy O; El Fattah RA; Sayed D
    Bone Marrow Transplant; 2005 Jan; 35(2):129-36. PubMed ID: 15568034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Kinetics of hematopoiesis after high-dose chemotherapy and autologous peripheral stem cell transplantation].
    Mayer J; Korístek Z; Pospísil Z; Vásová I; Adam Z; Hájek R; Krejcí M; Král Z; Navrátil M; Vorlícek J; Bourková L; Matýsková M; Adler J; Vinklárková J; Klabusay M; Koutná I; Hoffová V; Schmitzová D; Janovská E
    Cas Lek Cesk; 1999 Mar; 138(6):170-7. PubMed ID: 10510531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
    Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
    Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.